ArticleAMB Express2025
SETDB1 knockdown boosts recombinant protein in CHO cells via epigenetic transcriptional silencing.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Chinese hamster ovary (CHO) cells serve as the predominant mammalian expression system for recombinant protein production. However, clonal heterogeneity and instability in recombinant protein expression remain significant challenges. SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) catalyzes histone 3 lysine 9 trimethylation (H3K9me3), a critical epigenetic modification regulating gene expression. Despite its functional importance, the dynamics of SETDB1 expression and its regulatory impacts in CHO cells remain poorly characterised. Through transcriptomic analysis of high- and low monoclonal antibody (mAb)-producing CHO clones, we identified SETDB1 as a key modulator of mAb expression. Notably, SETDB1 expression exhibited an inverse correlation with recombinant protein levels in transfected CHO cells. SETDB1-knockdown (SETDB1-KD) CHO cells demonstrated significantly enhanced recombinant antibody-specific productivity. The use of small-molecule SETDB1 inhibitors resulted in a comparable enhancement of transgene expression to that observed with SETDB1 silencing. During extended cultivation, recombinant protein production progressively diminished concurrent with declining SETDB1-KD efficacy. This temporal correlation demonstrates that SETDB1-mediated epigenetic regulation is essential for maintaining both recombinant protein titers and chromosomal stability in industrial biomanufacturing processes. Transcriptome dynamics analysis revealed that SETDB1 silencing induces transcriptional pattern remodeling in transfected cells. These findings elucidate SETDB1's regulatory role in CHO cells and provide actionable insights for the optimisation of recombinant protein production through cell engineering strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.